{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:08:44Z","timestamp":1794002924711,"version":"4.8.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020068","name":"Topconsortium voor Kennis en Innovatie","doi-asserted-by":"publisher","award":["LSHM22041"],"award-info":[{"award-number":["LSHM22041"]}],"id":[{"id":"10.13039\/501100020068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.psychres.2025.116355","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T17:35:10Z","timestamp":1736098510000},"page":"116355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review"],"prefix":"10.1016","volume":"345","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-7341","authenticated-orcid":false,"given":"Juliana","family":"Lima Constantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Godschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-8447","authenticated-orcid":false,"given":"Jens H.","family":"van Dalfsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien K.E.","family":"Veraart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-9647","authenticated-orcid":false,"given":"Jan","family":"Spijker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5737-9600","authenticated-orcid":false,"given":"Eric","family":"van Exel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.psychres.2025.116355_bib0001","first-page":"785","article-title":"Pharmacologic management of adult depression","volume":"77","author":"Adams","year":"2008","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.psychres.2025.116355_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121803","article-title":"Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine","volume":"326","author":"Adzic","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.psychres.2025.116355_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109313","article-title":"Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites","volume":"223","author":"Ago","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2025.116355_bib0004","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fpsyt.2020.00844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"11","author":"Andrashko","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2025.116355_bib0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17512433.2022.2112949","article-title":"Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder","volume":"15","author":"Bobo","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116355_bib0006","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/NDT.S339090","article-title":"Effect of sleep disturbance on efficacy of esketamine in treatment-resistant depression: findings from randomized controlled trials","volume":"17","author":"Borentain","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2025.116355_bib0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jad.2020.11.111","article-title":"How does borderline personality disorder affect management and treatment response of patients with major depressive disorder? A comprehensive review","volume":"281","author":"Ceresa","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116355_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2022.07.054","article-title":"The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder","volume":"315","author":"Chen","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.psychres.2025.116355_bib0009","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00213-020-05737-z","article-title":"Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression","volume":"238","author":"Chen","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2025.116355_bib0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jad.2020.11.045","article-title":"Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials","volume":"281","author":"Chen","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116355_bib0011","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jad.2019.09.010","article-title":"The NEO-FFI domain of openness to experience moderates ketamine response in treatment resistant depression","volume":"260","author":"Dale","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/JCP.0000000000001149","article-title":"Metabolic syndrome rather than body mass index is associated with treatment response to ketamine infusions","volume":"40","author":"Dale","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.psychres.2025.116355_bib0013","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/da.23193","article-title":"The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder","volume":"38","author":"Daly","year":"2021","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.psychres.2025.116355_bib0014","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.psychres.2023.115133","article-title":"Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder","volume":"323","author":"Danayan","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2025.116355_bib0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.psychres.2016.04.034","article-title":"Socio-demographic and clinical predictors of non-response\/non-remission in treatment resistant depressed patients: A systematic review","volume":"240","author":"De Carlo","year":"2016","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0016","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14491","article-title":"Effect of concomitant benzodiazepines on the antidepressant effects of ketamine: findings from the RAPID intravenous ketamine study","volume":"84","author":"Feeney","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2025.116355_bib0017","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1017\/S1461145705006280","article-title":"Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation","volume":"9","author":"Fregni","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.psychres.2025.116355_bib0019","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/NDT.S388164","article-title":"A systematic review assessing patient-related predictors of response to transcranial magnetic stimulation in major depressive disorder","volume":"19","author":"Gonterman","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/13651501.2018.1562077","article-title":"Repetitive transcranial magnetic stimulation (rTMS) for depression: outcomes in a United Kingdom (UK) clinical practice","volume":"23","author":"Griffiths","year":"2019","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"10","key":"10.1016\/j.psychres.2025.116355_bib0021","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4088\/JCP.14r09528","article-title":"Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors","volume":"76","author":"Haq","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2025.116355_bib0022","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2025.116355_bib0023","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.4088\/JCP.14m09049","article-title":"Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine","volume":"75","author":"Ionescu","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2025.116355_bib0024","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/npp.2013.149","article-title":"Relapse following successful electroconvulsive therapy for major depression: a meta-analysis","volume":"38","author":"Jelovac","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2025.116355_bib0025","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1002\/hup.2836","article-title":"Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression","volume":"37","author":"Jesus-Nunes","year":"2022","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116355_bib0026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jad.2022.10.020","article-title":"Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability","volume":"321","author":"Jha","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116355_bib0027","article-title":"Esketamine in depression: putative biomarkers from clinical research","author":"Johnston","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.psychres.2025.116355_bib0028","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/ph16081164","article-title":"Efficacy of ketamine with and without lamotrigine in treatment-resistant depression: a preliminary report","volume":"16","author":"Joseph","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0029","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41398-023-02451-0","article-title":"Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression","volume":"13","author":"Kopelman","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116355_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107494","article-title":"A hypothesis of monoamine (5-HT) - Glutamate\/GABA long neural circuit: aiming for fast-onset antidepressant discovery","volume":"208","author":"Li","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0031","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","article-title":"Prevalence of depression in the community from 30 countries between 1994 and 2014","volume":"8","author":"Lim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.psychres.2025.116355_bib0032","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jpsychires.2020.08.002","article-title":"Intravenous ketamine for postmenopausal women with treatment-resistant depression: results from the Canadian rapid treatment center of excellence","volume":"136","author":"Lipsitz","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2025.116355_bib0033","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/S1092852920002102","article-title":"Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian rapid treatment center of excellence","volume":"27","author":"Lipsitz","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.psychres.2025.116355_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2020.03.048","article-title":"Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: a preliminary study","volume":"271","author":"Liu","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116355_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2019.08.012","article-title":"Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression","volume":"259","author":"Liu","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0036","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0269881120978398","article-title":"Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity","volume":"35","author":"Lucchese","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116355_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.608499","article-title":"A clinical rationale for assessing the impact of childhood sexual abuse on adjunctive subcutaneous esketamine for treatment-resistant depression","volume":"12","author":"Magalhaes","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2025.116355_bib0038","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar. Disord."},{"key":"10.1016\/j.psychres.2025.116355_bib0039","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jad.2021.12.097","article-title":"A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings","volume":"301","author":"McInnes","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.psychres.2025.116355_bib0025a","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis","volume":"27","author":"Medeiros","year":"2022","journal-title":"Molecular psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2025.116355_bib0040","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.clinph.2021.01.030","article-title":"Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials","volume":"132","author":"Meyer","year":"2021","journal-title":"Clin. Neurophysiol."},{"issue":"5","key":"10.1016\/j.psychres.2025.116355_bib0041","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/npp.2014.298","article-title":"Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial","volume":"40","author":"Murrough","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2025.116355_bib0042","article-title":"Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response","author":"Murrough","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0043","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu039","article-title":"Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder","volume":"18","author":"Niciu","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116355_bib0044","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/ph12030133","article-title":"The impact of childhood maltreatment on intravenous ketamine outcomes for adult patients with treatment-resistant depression","volume":"12","author":"O'Brien","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2025.116355_bib0046","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jagp.2021.09.014","article-title":"Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study","volume":"30","author":"Ochs-Ross","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0047","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.psychres.2025.116355_bib0048","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.psychres.2025.116355_bib0049","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2025.116355_bib0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jad.2016.08.019","article-title":"The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method","volume":"205","author":"Peeters","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116355_bib0051","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jad.2016.10.026","article-title":"Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion","volume":"208","author":"Pennybaker","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0052","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2025.116355_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063095","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open."},{"issue":"12","key":"10.1016\/j.psychres.2025.116355_bib0054","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","article-title":"International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators","volume":"27","author":"Price","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"14","key":"10.1016\/j.psychres.2025.116355_bib0056","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.psychres.2025.116355_bib0057","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00406-023-01716-5","article-title":"Clinical predictors of suicidal ideation, suicide attempts and suicide death in depressive disorder: a systematic review and meta-analysis","volume":"274","author":"Riera-Serra","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0058","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/00048674231203898","article-title":"Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression","volume":"58","author":"Rodgers","year":"2024","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2025.116355_bib0059","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/ijerph15040771","article-title":"Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder","volume":"15","author":"Rong","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"10","key":"10.1016\/j.psychres.2025.116355_bib0060","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900625","article-title":"Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States","volume":"71","author":"Ross","year":"2020","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0061","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13651501.2017.1297834","article-title":"Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression","volume":"21","author":"Rybakowski","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0062","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41746-023-00817-8","article-title":"AI-assisted prediction of differential response to antidepressant classes using electronic health records","volume":"6","author":"Sheu","year":"2023","journal-title":"NPJ. Digit. Med."},{"issue":"11","key":"10.1016\/j.psychres.2025.116355_bib0063","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S1461145714001011","article-title":"Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression","volume":"17","author":"Shiroma","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0064","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2024.5756","article-title":"Management of depression in adults: a review","volume":"332","author":"Simon","year":"2024","journal-title":"JAMa"},{"issue":"5","key":"10.1016\/j.psychres.2025.116355_bib0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/02698811221084055","article-title":"The antidepressant effect and safety of non-intranasal esketamine: a systematic review","volume":"36","author":"Smith-Apeldoorn","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2025.116355_bib0066","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2025.116355_bib0067","first-page":"364","article-title":"New numbers on the duration of major and minor depressive episodes in the general population; results from NEMESIS-2","volume":"60","author":"Ten Have","year":"2018","journal-title":"Tijdschr. Psychiatr."},{"issue":"10","key":"10.1016\/j.psychres.2025.116355_bib0068","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/0269881118793104","article-title":"Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness","volume":"32","author":"Thomas","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116355_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115165","article-title":"Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray","volume":"323","author":"Turkoz","year":"2023","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1192\/bjp.2017.28","article-title":"Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis","volume":"212","author":"van Diermen","year":"2018","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2025.116355_bib0071","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20r13459","article-title":"Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: a systematic review","volume":"82","author":"Veraart","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2025.116355_bib0072","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/acps.13096","article-title":"Association between depression subtypes and response to repeated-dose intravenous ketamine","volume":"140","author":"Wang","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0073","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s43440-020-00203-1","article-title":"Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis","volume":"73","author":"Wang","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.psychres.2025.116355_bib0074","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/a-2179-8884","article-title":"Factors associated with antidepressant effects of ketamine: a reanalysis of double-blind randomized placebo-controlled trial of intravenous ketamine for treatment-resistant depression","volume":"57","author":"Yonezawa","year":"2024","journal-title":"PharmacoPsychiatry"},{"key":"10.1016\/j.psychres.2025.116355_bib0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2023.04.015","article-title":"Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression","volume":"333","author":"Zavaliangos-Petropulu","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.psychres.2025.116355_bib0076","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116355_bib0077","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2025.116355_bib0078","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/0269881119827811","article-title":"Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder","volume":"33","author":"Zheng","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116355_bib0079","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jad.2020.01.001","article-title":"Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis","volume":"264","author":"Zhou","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.psychres.2025.116355_bib0080","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0269881118798614","article-title":"Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression","volume":"32","author":"Zhou","year":"2018","journal-title":"J. Psychopharmacol."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:39:45Z","timestamp":1777336785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":80,"alternative-id":["S0165178125000046"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116355","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116355"}}